After approval was obtained in October 2018, the kidney transplantation study with RESCAP® platform technology under supervision of PI Dr Joost van der Heijden from VUmc Amsterdam found its “First Patient In” status in June 2019. Ischemic injury in kidneys to be transplanted are cause of serious complications and limit overall success rate of transplantation. With RESCAP® we expect to reduce overall SIRS complication s peri-and post surgery and expect to improve patients well being following surgery. A follow up study is planned with non-heart beating donor kidneys as soon as this study is finalised in a multi-center approach
Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today
